Nefropatías vasculareshipertensión vasculorrenal y nefropatía isquémica

  1. Tocora, D.G. Gaitán
  2. del Valle, K.M. Pérez
  3. Hernández Sevillano, B.
  4. de la Fuente, G. de Arriba
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2019

Titre de la publication: Enfermedades nefrourinarias (III) Hipertensión y enfermedades vasculares renales

Serie: 12

Número: 81

Pages: 4779-4785

Type: Article

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2019.06.004 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Vascular nephropathies encompass a group of disorders sharing the impairment of main kidneys vessels, resulting in a kidney arterial flow reduction, which commonly is associated with kidney function impairment and secondary arterial hypertension. Arteriosclerotic cause is the most frequent etiology; however, the commonest is fibromuscular dysplasia, mainly in youngest patients. Early diagnosis, using the proper and safer procedures, is required. Regarding their treatment, arterial pressure control and the preservation of renal function are essentials.

Références bibliographiques

  • Adamczak M, Wiecek A. Ischemic nephropathy : pathogenesis and treatment. Nefrologia. 2012;32(4):432-8.
  • Balzer KM, Pfeiffer T, Rossbach S, Voiculescu A, Modder U, Godehardt E. Prospective randomized trial of operative vs interventional treatment for renal artery ostial occlusive disease (RAOOD). J Vasc Surg. 2009;49(3):667-74; discusión 74-5.
  • Bavishi C, de Leeuw PW, Messerli FH. Atherosclerotic renal artery stenosis and hypertension: pragmatism, pitfalls, and perspectives. Am J Med. 2016;129(6):635 e5-e14
  • Cooper CJ, Murphy TP, Cutlip DE, Jamerson K, Henrich W, Reid DM. Stenting and medical therapy for atherosclerotic renal artery stenosis. N Engl J Med. 2014;370(1):13-22.
  • Dworkin LD, Cooper CJ. Clinical practice. Renal artery stenosis. N Engl J Med. 2009;361(20):1972-8.
  • Gornik HL, Persu A, Adlam D, Aparicio LS, Azizi M, Boulanger M. First international consensus on the diagnosis and management of fibromuscular dysplasia. J Hypertens. 2019;37(2):229-52.
  • Hackam DG, Duong-Hua ML, Mamdani M, Li P, Tobe SW, Spence JD. Angiotensin inhibition in renovascular disease: a population based cohort study. Am Heart J. 2008;156(3):549-55.
  • Herrmann SM, Textor SC. Current concepts in the treatment of renovascular hypertension. Am J Hypertens. 2018;31(2):139-49.
  • Losito A, Errico R, Santirosi P, Lupattelli T, Scalera GB, Lupattelli L. Long term follow up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant. 2005;20(8):1604-9.
  • Sanz L. Nefropatía isquémica y enfermedad ateroembólica. Nefrología clínica. 4ª ed. Madrid: Panamericana; 2013. p. 325-8.
  • Textor SC. Current approaches to renovascular hypertension. Med Clin North Am. 2009;93(3):717-32.
  • Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens. 2010;23(11):1159-69.
  • Textor SC. Renal arterial disease and hypertension. Med Clin North Am. 2017;101(1):65-79.
  • Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C. Revascularization versus medical therapy for renal artery stenosis. N Engl J Med. 2009;361(20):1953-62
  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.
La source de données: Dialnet